


Berlin-Marienfelde, 25. März 2004 Fortbildungsveranstaltung für den Öffentlichen Gesundheitsdienst 2004


Aktuelle Entwicklungen in Infektionsschutz- und Bioterrorismus- Prävention

Prof. Dr. Reinhard *Burger*Robert Koch-Institut











M. Özel, Robert Koch-Institut, Berlin



M. Özel, Robert Koch-Institut, Berlin



M. Özel, Robert Koch-Institut, Berlin



List of pathogens for public health considerations (1)

CDC Agent Categ.		Syndromic surveillance	Case based surveillance
A	Variola major (smallpox)	Pox	No value
Α	Bacillus anthracis (anthrax)	Pneumonic	Yes
A	Yersinia pestis (plague)	Pneumonic or	Yes
Α	Clostridium botulinum (botulism)	Febrile	
Α	Francisella tularensis (tularaemia)	No	Yes
A	VHF viruses (Arena, Bunya, Filo, Flavi)	Pneumonic Hemorrhagic fever	Yes


A = easily disseminated or transmitted person-to-person, high mortality, major public health impact, might cause public panic and social disruption; require special action for preparedness

List of pathogens for public health considerations (2)

CDC Categ.	Agent	Syndromic surveillance	Case based surveillance
В	Coxiella burnetti	Febrile	Yes
В	Brucella	Febrile	Yes
В	Burkholderia mallei	Febrile	No Value
В	Burkholderia pseudomalle	Febrile	No Value
В	Alphaviruses	Encephalitis	No value
В	Rickettsia prowazekii	Febrile	No value
В	Toxins	Neurological	No value
В	Chlamydia psittaci	Pneumonic	?
В	E.coli 0157:H7 HUS	Diarrhea	Yes

8

Responsibilities for biological risk management (before 2000)



Defense against Bioterrorism: Required Expertise

- Diagnostics
- Epidemiology of infectious diseases / Field epidemiology
- Communication
- Management of epidemic events

Challenge for medical microbiologists (1)

- Appropriate research projects for defense against biological agents
- USA investment in defense against bioterrorism :
 - \$ 5.9 Billion fiscal year 2003
 - incl. \$ 1.75 Billion for NIH
- Major Goals: Diagnostics
 - Therapeutics
 - (ideally) broad spectrum, "universal"
 - Vaccine
 - Immune modulators (incl. innate immunity)
- Benefit for naturally emerging or re-emerging Infectious diseases

Challenge for medical microbiologists (2)

- Development of rapid and reliable detection systems / pathogen identification
- Speed and sensitivity
- Specificity (no false pos. / no false neg.)
- Innovative systems

Innovative Systems

Examples:

- Chip-technology / microarrays
- B-Lymphocyte cell lines,
 Ag-specific activation,
 Ca-sens. bioluminescence,
 results in seconds

Challenge for medical microbiologists (3) Need recognized for basic research!

- Biology of the microbe targets for - diagnostics - drugs - vaccines (protective epitopes)
- Host response / host pathogen interaction
 - pathomechanisms
 - receptors
 - immune regulation
 - escape mechanisms

Microbiological diagnostics in bioterrorism

- Rapid exclusion of a bioterroristic agent
- Rapid detection and confirmation of bioterroristic agents or infection
- Estimation of the risk for infection / dissemination
- Preventive measures against spread

Detection of bioterroristic agents

- Conventional diagnostics (culture , including selective media, microscopy , incl. El. Microscope)
- Nucleic acid amplification tests using agent-specific primers (PCR , Real - Time PCR , sequencing)
- Immunological assays (Ag detection, Ab detection)
- Animal experiment

Requirements for Preparedness

Laboratories

- Increase in the capacity of the laboratories both at federal and state levels
- SOPs / Training
- Development of new tests
 - Identification by culture, molecular biology, El. microscopy
- Broader spectrum of tests / pathogens
- Robert Koch-Institute: 24 h on duty / 7 days / week

Sharing of information

- Military Experts
- Civil Protection
- Federal Criminal Office (BKA)
- Federal Intelligence Service (BND)
- German Postal Service
- Federal Ministries
- Ministries of the States ("Länder")
 (esp. in the field of public health and
 their officials responsible for epidemics)
- Local Health Offices

Biosafety and Laboratory Security for BSL - 2, - 3 and - 4

- Risk of laboratory infections and release (e. g. SARS!)
- Optimal laboratory practices
- Proper containment and facilities
- Training of personnel / employee security (unintentional incidents; biosafety)
- Access security
- Physical security / unauthorized entry (including deliberate removal)
- Inventory / accountability
- Transport problems

Awareness of new agents / GMO (1)

 "Limitless " new possibilities of genetically modified microorganisms

Examples:

- Ectromelia (mousepox) expressing IL 4 highly lethal for ordinarily resistent strains
- Animal pox viruses closely related to human smallpox

"New"agents/GMO (2)

- Alteration of surface antigens or other properties
 - delayed detection, erroneous treatment
- Escape from natural host defense or from vaccine - induced immunity
- Required expertise and tools widely available
- Worthwhile from a bioterrorist's point of view ??'

Development of antimicrobials, immunotherapeutics, antitoxins

- Increased generation and evalution of new / novel substances (e. g. soluble receptors)
- Development of high throughput screening systems
- Agent specific development
- Replacement of suboptimal, available drugs
 (amount, function, e. g. Vaccinia immunoglobulin)
- Animal models needed
- Improved cooperation between academia - industry - government

Problems in diagnostics upon suspected deliberate release: Clinical vs environmental samples

- Massive contamination with irrelevant but similar / closely related organisms
- Inhibiting substances present (culture, NAT)
- Low microbial number
- Initial absence of typical clinical symptoms

Management of exceptional epidemic events in Germany

The Anthrax Experience

Anthrax: Situation

Notifiable disease / agent (last case: 1994)

- more than 4,000 investigated threats
 (samples tested for anthrax: white powder, but also Kleenex, clothes, etc.)
- two "false positive" results


not a single confirmed case

Anthrax: Consequences / Problems

- Only a small number of laboratories were able to test properly (BSL 3, controls ...)
- Their capacities were quickly exhausted
- Public fear (antibiotics!)
- Huge demand for information and recommendations
- Immense reaction in the media


(Inhalational) Anthrax (B. anthracis)

- Inhalation of spores, transport in body
- Germination and replication;




- Virulence factors :
- Formation of plasmid coded toxins
 - EF (Edema factor) associating with
 - PA (Protective antigen) associating with
 - LF (Lethal factor)
- Antiphagocytic capsule

Bacillus anthracis



Detection of *B. anthracis* with Real - Time - PCR

detection limit: 10 copies






"Shipping container " at the L3/S3-Laboratory of the Robert Koch-Institute



"Shipment" of the first suspected Anthrax - threat letter to the Robert Koch-Inst. Oct 10, 2001



James Hughes, Julie Gerberding, CDC, Oct 2002 Anthrax Lesson:

Importance of the " Golden Triangle of response "

between Clinician

Clinical microbiologists

Health-care delivery system

Public health officials

Importance of surge capacity (diagnostics, health-care)

Cooperation with industry?

Centre for Biological Security at the Robert Koch-Institute

- Federal Information Centre for Bioterrorism and Biological Safety (IBBS)
- Diagnostics of relevant biological warfare (BW) agents
- Scenario modelling to prepare against bioterroristic attacks (e. g. smallpox vaccination program)
- Co-ordination in Germany of national and international programs for biological safety

Centre for Biological Security

- **ZBS 1** Highly pathogenic viral agents (BSL 3 -, BSL 4)
- **ZBS 2** Highly pathogenic bacteria, fungi und parasites (BSL 3)
- **ZBS 3** Toxins (microbial, others)
- **ZBS 4** Rapid diagnostics, methods, standardization, visualization
- IBBS (Informationsstelle des Bundes für Biologische Sicherheit) scenarios, aspects of the management of bioterroristic attacks, coordination of measures, information of the public and experts, international contacts, et al.